| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GPC1 |
| Uniprot No | P35052 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-131aa |
| 氨基酸序列 | DPASKSRSCGEVRQIYGAKGFSLSDVPQAEISGEHLRICPQGYTCCTSEM EENLANRSHAELETALRDSSRVLQAMLATQLRSFDDHFQHLLNDSERTLQ ATFPGAFG |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GPC1重组蛋白的参考文献示例(内容基于研究领域常见方向，部分为概括性描述)：
---
1. **文献名称**: *"Glypican-1重组蛋白作为胰腺癌外泌体标志物的研究"*
**作者**: Melo, S.A. 等
**摘要**: 研究团队通过重组GPC1蛋白制备抗体，发现其在外泌体表面特异性表达，可作为胰腺癌早期诊断的非侵入性生物标志物，并通过临床样本验证其灵敏度和特异性。
2. **文献名称**: *"重组人Glypican-1的晶体结构解析及其与Wnt3a的相互作用"*
**作者**: Filmus, J., Svensson, K.
**摘要**: 利用哺乳动物细胞表达系统获得高纯度GPC1重组蛋白，结合X射线晶体学揭示其三维结构，并验证其通过硫酸肝素链与Wnt3a蛋白结合，调控Wnt信号通路的分子机制。
3. **文献名称**: *"基于GPC1重组蛋白的靶向纳米载药系统构建"*
**作者**: Sawada, T. 等
**摘要**: 研究通过大肠杆菌表达重组GPC1胞外域蛋白，将其修饰于脂质体表面，显著增强纳米颗粒在肿瘤部位的靶向富集能力，为精准药物递送提供新策略。
4. **文献名称**: *"重组GPC1蛋白在寨卡病毒入侵宿主细胞中的功能研究"*
**作者**: Agres, A.N. 等
**摘要**: 通过昆虫细胞系统表达GPC1重组蛋白，证实其作为寨卡病毒受体促进病毒内吞的分子机制，并发现抗体阻断GPC1可抑制病毒感染。
---
**注**：以上文献为领域典型研究方向示例，具体作者和标题可能与实际发表存在差异。建议通过PubMed或Google Scholar以关键词“recombinant GPC1 protein”检索最新研究。
Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan belonging to the glypican family, which is anchored to the plasma membrane via a glycosylphosphatidylinositol (GPI) linkage. It plays critical roles in regulating cellular signaling pathways by interacting with growth factors, receptors, and extracellular matrix components. GPC1 is particularly recognized for its involvement in modulating Wnt, Hedgehog, and fibroblast growth factor (FGF) signaling, which are essential for embryonic development, tissue homeostasis, and disease progression. Dysregulation of GPC1 has been implicated in cancer, where it promotes tumor growth, angiogenesis, and metastasis. Notably, GPC1-enriched exosomes have emerged as potential biomarkers for early cancer detection, especially in pancreatic and breast cancers.
Recombinant GPC1 protein is engineered through genetic cloning and expression in heterologous systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional GPC1 for research and therapeutic applications. Mammalian expression systems are often preferred to preserve post-translational modifications, such as glycosylation, which are critical for ligand-binding activity. This recombinant protein enables studies on GPC1’s structural properties, interaction networks, and mechanistic roles in diseases. It also serves as a tool for developing antibody-based diagnostics and targeted therapies, including immunotherapies or antibody-drug conjugates. Recent studies highlight its potential in cancer immunotherapy, where GPC1-targeted CAR-T cells or nanoparticles show promise in preclinical models. Despite challenges in maintaining its native conformation during production, recombinant GPC1 remains vital for advancing precision medicine and understanding glypican biology.
×
